NJII Launches Cell and Gene Therapy Manufacturing Center
The center will be located at NJIT’s Life Sciences and Engineering center and will feature two good manufacturing practices suites that are expected to be completed and operational during the summer of 2020.
The Biopharma Division of the New Jersey Innovation Institute (NJII), a New Jersey Institute of Technology (NJIT) corporation, announced on May 4, 2020 that it is launching BioCentriq, a cell and gene therapy production and manufacturing center in Newark, NJ.
According to a company press release, the center will be located at NJIT’s Life Sciences and Engineering center and will feature two good manufacturing practices suites that are expected to be completed and operational during the summer of 2020.
“BioCentriq will help bring innovative and novel therapies to clinical trials, providing a venue for established companies and start-ups alike. It is also a unique training ground for the workforce of the future,” said Dr. Haro Hartounian, senior vice-president and general manager of Biopharma at NJII, in the press release. “We are grateful to all our partners who have supported us financially and with in-kind donations of equipment and supplies, as well as the industry leaders who serve on our advisory board and lend us their expertise.”
Source: NJII
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
